Edition:
United States

Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Morphosys AG receives additional patents on novel antibody platform Ylanthia in the U.S. and first patent in China


Friday, 18 Jul 2014 01:31am EDT 

Morphosys AG:Announces that the U.S. Patent and Trademark Office (USPTO) and the State Intellectual Property Office of China have granted additional patents covering the company's latest antibody platform Ylanthia.